cause – Page 65 – Communicable Diseases Research

COVID-19 Post-acute Sequelae Among Adults: 12 Month Mortality Risk

Medicine

Published on 2021-12-012022-10-31
Journal: Frontiers in Medicine [Category] COVID-19,

Encountering the social determinants of health on a COVID-19 ICU: Frontline providers’ perspectives on inequality in a time of pandemic

Research article

Published on 2021-12-012022-10-05
Journal: SSM - Qualitative Research in Health [Category] 유전자 메커니즘,

[키워드] black Care Causal attributions cause clinician consequence COVID-19 Critical Drawing equity Health Health inequalities healthcare ICU ICUs Impact IMPROVE individual intensive care unit Latinx Nurse pandemic Patient Perspective question Racial raise Registered RRT social determinant social determinants of health
[DOI] 10.1016/j.ssmqr.2021.100001 [Article Type] Research article

Docking-based virtual screening and identification of potential COVID-19 main protease inhibitors from brown algae

Research article

Published on 2021-12-012022-10-05
Journal: South African Journal of Botany [Category] 신약개발,

E484K mutation in SARS-CoV-2 RBD enhances binding affinity with hACE2 but reduces interactions with neutralizing antibodies and nanobodies: Binding free energy calculation studies

SARS-CoV-2 RBD의 E484K 돌연변이는 hACE2와의 결합 친화도를 향상시키지만 중화 항체 및 나노바디와의 상호작용을 감소시킵니다. 결합 자유 에너지 계산 연구

Article

Published on 2021-12-012022-09-11
Journal: Journal of molecular graphics & modelling [Category] SARS, 변종, 유전자 메커니즘, 진단,

[키워드] addition All-atom molecular dynamics simulation angiotensin Angiotensin-converting enzyme antibody binding binding affinities binding affinity Burial cause caused compensating conformational contribute COVID-19 COVID-19 disease death decrease drug design E484K E484K mutation Effect effective effective vaccine Effective vaccines Effectiveness electrostatic interaction ENhance enzyme group hACE2 Human human Angiotensin-converting enzyme Human angiotensin-converting enzyme 2 hydrogen Hydrogen bond hydrogen bonds immune response Impact IMPROVE Infection information Interaction investigated leads molecular molecular dynamics Molecular mechanics molecular mechanism mutant mutate Mutation mutations nanobodies nanobody Neutralizing Neutralizing antibodies neutralizing antibody pandemic polar RBD receptor Receptor binding receptor hACE2 Receptor-binding domain Recognition reduce reduced residue SARS-CoV-2 SARS-CoV-2 RBD selected significantly surface area the binding affinity the receptor-binding domain Transmissibility Vaccine development variant variants
[DOI] 10.1016/j.jmgm.2021.108035 PMC 바로가기 [Article Type] Article

COVID-19-Induced New-Onset Diabetes: Trends and Technologies

COVID-19 유발 신규 당뇨병: 동향 및 기술

Review

Published on 2021-12-012022-09-11
Journal: Diabetes [Category] SARS, 유전자 메커니즘,

Integrated multi-omics approach identified molecular mechanism and pathogenetic processes of COVID-19 that affect patient with Parkinson’s disorder

Research article

Published on 2021-12-012022-10-05
Journal: Saudi Journal of Biological Sciences [Category] 유전자 메커니즘,

Fluvoxamine for the Early Treatment of SARS-CoV-2 Infection: A Review of Current Evidence

SARS-CoV-2 감염의 조기 치료를 위한 Fluvoxamine: 현재 증거 검토

Review

Published on 2021-12-012022-09-11
Journal: Drugs [Category] SARS, 비임상, 임상,

[키워드] anti-inflammatory effect Anti-inflammatory effects appear available data breath Canada cause Clinical deterioration clinician condition controlled trials COVID-19 COVID-19 pandemic COVID-19 treatment COVID-19 treatment guidelines current cytokine production Decision making Dosing early treatment Efficacy fluvoxamine Infection inhibitor investigators knowledge long-lasting mechanism medication meeting morbidity morbidity and mortality NIH observational study potential mechanism potential mechanisms Psychiatric randomized clinical trial Randomized controlled trial receptor reduce Research review Safe SARS-CoV-2 SARS-COV-2 infection selective Sepsis Serotonin Treatment Trial USA
[DOI] 10.1007/s40265-021-01636-5 PMC 바로가기 [Article Type] Review

Clinical Characteristics, Diagnosis, Treatment, and Mortality Rate of TB/COVID-19 Coinfectetd Patients: A Systematic Review

Medicine

Published on 2021-12-012022-10-31
Journal: Frontiers in Medicine [Category] COVID-19,

[키워드] addition Case report case sery cause Characteristics China clinical Coinfection collected Comorbidity coronavirus cough COVID-19 COVID-19 epidemic COVID-19 patient COVID-19-related death diabete diagnosed died discharged patient distress enrolled Epidemic Fever health system hypertension India indicated less limitation majority material men Mortality mortality rate National novel Patient patients Prevalence Prevent Rate respiratory symptom review screened severity Spread suffered TB TB patient the disease Threats Treatment Tuberculosis underlying conditions was performed Web of Science with COVID-19 women worsening
[DOI] 10.3389/fmed.2021.740593 PMC 바로가기 [Article Type] Medicine

Analysis and comparison of physiochemical properties, mutations and glycosylation patterns between RNA polymerase and membrane protein of SARS-CoV and SARS-CoV-2

Original Article

Published on 2021-12-012022-10-30
Journal: Molecular Biology Research Communications [Category] COVID-19,

Anakinra as a potential alternative in the treatment of severe acute respiratory infection associated with SARS-CoV-2 refractory to tocilizumab

토실리주맙에 불응성인 SARS-CoV-2와 관련된 중증 급성 호흡기 감염 치료의 잠재적인 대안으로서의 아나킨라

Case Reports

Published on 2021-12-012022-09-11
Journal: Reumatología clinica [Category] 진단, 치료제,

[키워드] (Tocilizumab Acute respiratory infection Anakinra anti-IL-1 anti-IL-6 anti-IL-6 receptor anti-IL-6 treatment antibodies Antiviral Atypical Atypical pneumonia Case report cause Clinical outcome coronavirus disease Coronavirus disease 2019 COVID-19 cytokine Cytokine storm diagnosed dysregulation English haemophagocytic lymphohistiocytosis Health Organization IL-1 IL-6 immune system Inflammatory response multiorgan failure OMS Pandemia pandemic Pneumonia Produce receptor respiratory respiratory infection RNA virus SARS-CoV-2 severe respiratory infection Spanish Tocilizumab Tormenta de citoquinas. Treatment Trigger triggering triggers virus virus RNA WHO World Health Organization
[DOI] 10.1016/j.reumae.2020.06.008 PMC 바로가기 [Article Type] Case Reports